Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 572

1.

A comparison of the effects of raloxifene and conjugated equine estrogen on bone and lipids in healthy postmenopausal women.

Reid IR, Eastell R, Fogelman I, Adachi JD, Rosen A, Netelenbos C, Watts NB, Seeman E, Ciaccia AV, Draper MW.

Arch Intern Med. 2004 Apr 26;164(8):871-9.

PMID:
15111373
2.

[A randomised clinical trial to study the effects of raloxifene hydrochloride on bone mineral density, biochemical markers of bone metabolism and serum lipids in postmenopausal women].

Zheng SR, Wu YY, Zhang ZL, Yang X, Hui Y, Zhang Y, Chen SL, Den WH, Liu H, Ekangaki A, Stocks J, Harper K, Liu JL.

Zhonghua Fu Chan Ke Za Zhi. 2003 Apr;38(4):226-9. Chinese.

PMID:
12885371
3.

Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in postmenopausal women: a randomized clinical trial in Beijing.

Zheng S, Wu Y, Zhang Z, Yang X, Hui Y, Zhang Y, Chen S, Deng W, Liu H, Ekangaki A, Stocks J, Harper K, Liu J.

Chin Med J (Engl). 2003 Aug;116(8):1127-33.

PMID:
12935394
4.

Effects of conjugated equine estrogens or raloxifene on lipid profile, coagulation and fibrinolysis factors in postmenopausal women.

Dias AR Jr, Melo RN, Gebara OC, D'Amico EA, Nussbacher A, Halbe HW, Pinotti JA.

Climacteric. 2005 Mar;8(1):63-70.

PMID:
15804733
5.

Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.

Jolly EE, Bjarnason NH, Neven P, Plouffe L Jr, Johnston CC Jr, Watts SD, Arnaud CD, Mason TM, Crans G, Akers R, Draper MW.

Menopause. 2003 Jul-Aug;10(4):337-44.

PMID:
12851517
6.

Effects of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis: a multi-center, randomized, placebo-controlled clinical trial.

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harper K.

Chin Med J (Engl). 2004 Jul;117(7):1029-35.

PMID:
15265377
7.

Long-term effects of raloxifene on bone mineral density, bone turnover, and serum lipid levels in early postmenopausal women: three-year data from 2 double-blind, randomized, placebo-controlled trials.

Johnston CC Jr, Bjarnason NH, Cohen FJ, Shah A, Lindsay R, Mitlak BH, Huster W, Draper MW, Harper KD, Heath H 3rd, Gennari C, Christiansen C, Arnaud CD, Delmas PD.

Arch Intern Med. 2000 Dec 11-25;160(22):3444-50.

PMID:
11112238
8.

Treatment of postmenopausal women with osteoporosis or low bone density with raloxifene. Raloxifene Study Group.

Meunier PJ, Vignot E, Garnero P, Confavreux E, Paris E, Liu-Leage S, Sarkar S, Liu T, Wong M, Draper MW.

Osteoporos Int. 1999;10(4):330-6. Erratum in: Osteoporos Int 1999;10(5):433.

PMID:
10692984
9.

A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.

Draper MW, Flowers DE, Huster WJ, Neild JA, Harper KD, Arnaud C.

J Bone Miner Res. 1996 Jun;11(6):835-42.

PMID:
8725181
10.

[Effect of raloxifene hydrochloride on bone mineral density, bone metabolism and serum lipids in Chinese postmenopausal women with osteoporosis].

Liu JL, Zhu HM, Huang QR, Zhang ZL, Li HL, Qin YJ, Zhang Y, Wei DL, Lu JH, Liu H, Chen XP, Liu YJ, Ekangaki A, Zheng YM, Diez-Perez A, Harpe K.

Zhonghua Yi Xue Za Zhi. 2004 Feb 17;84(4):269-73. Chinese.

PMID:
15059505
11.

Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.

Delmas PD, Bjarnason NH, Mitlak BH, Ravoux AC, Shah AS, Huster WJ, Draper M, Christiansen C.

N Engl J Med. 1997 Dec 4;337(23):1641-7.

12.

Effect of hormone replacement therapy, tibolone and raloxifene on serum lipids, apolipoprotein A1, apolipoprotein B and lipoprotein(a) in Greek postmenopausal women.

Christodoulakos GE, Lambrinoudaki IV, Panoulis CP, Papadias CA, Kouskouni EE, Creatsas GC.

Gynecol Endocrinol. 2004 May;18(5):244-57.

PMID:
15346660
14.

Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.

Mijatovic V, van der Mooren MJ, Kenemans P, de Valk-de Roo GW, Netelenbos C.

Menopause. 1999 Summer;6(2):134-7.

PMID:
10374220
15.

Simvastatin, transdermal patch, and oral estrogen-progestogen preparation in early-postmenopausal hypercholesterolemic women: a randomized, placebo-controlled clinical trial.

Vigna GB, Donegà P, Zanca R, Barban A, Passaro A, Pansini F, Bonaccorsi G, Mollica G, Fellin R.

Metabolism. 2002 Nov;51(11):1463-70.

PMID:
12404199
16.

A comparison of the effects of raloxifene and estrogen on bone in postmenopausal women.

Prestwood KM, Gunness M, Muchmore DB, Lu Y, Wong M, Raisz LG.

J Clin Endocrinol Metab. 2000 Jun;85(6):2197-202.

PMID:
10852452
17.

Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.

Miller PD, Chines AA, Christiansen C, Hoeck HC, Kendler DL, Lewiecki EM, Woodson G, Levine AB, Constantine G, Delmas PD.

J Bone Miner Res. 2008 Apr;23(4):525-35. Erratum in: J Bone Miner Res. 2008 Jun;23(6):972.

18.

The effect of hormone replacement therapy on the levels of serum lipids, apolipoprotein AI, apolipoprotein B and lipoprotein (a) in Turkish postmenopausal women.

Bayrak A, Aldemir DA, Bayrak T, Corakçi A, Dursun P.

Arch Gynecol Obstet. 2006 Aug;274(5):289-96. Epub 2006 Jun 30.

PMID:
16810536
19.

Effect of hormone replacement therapy on lipids in perimenopausal and early postmenopausal women.

Ossewaarde ME, Bots ML, Bak AA, Van Der Schouw YT, Witteman JC, Planellas J, Bennink HJ, Grobbee DE.

Maturitas. 2001 Sep 28;39(3):209-16.

PMID:
11574180
20.

Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial.

Lufkin EG, Whitaker MD, Nickelsen T, Argueta R, Caplan RH, Knickerbocker RK, Riggs BL.

J Bone Miner Res. 1998 Nov;13(11):1747-54.

Supplemental Content

Support Center